Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
Prelude Therapeutics (Nasdaq: PRLD), a clinical-stage precision oncology company, has announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami, FL on March 11, 2025.
Key executives participating in a fireside chat at 12:30 p.m. ET include:
- Kris Vaddi, Ph.D., Chief Executive Officer
- Jane Huang, M.D., President and Chief Medical Officer
- Bryant Lim, Chief Financial Officer
The event will be accessible via live webcast on the Company's website under Events and Presentations, with the recording remaining available for 90 days. Prelude Therapeutics specializes in developing innovative medicines for cancer patients, focusing on:
- First-in-class SMARCA2 degraders (IV and oral)
- CDK9 inhibitor development
- Precision ADCs (Degrader Antibody Conjugates) through partnerships
Prelude Therapeutics (Nasdaq: PRLD), una compagnia di oncologia di precisione in fase clinica, ha annunciato la sua partecipazione alla 27ª Conferenza Globale Annuale sulla Salute di Barclays a Miami, FL, il 11 marzo 2025.
I principali dirigenti che parteciperanno a una chiacchierata informale alle 12:30 ET includono:
- Kris Vaddi, Ph.D., Amministratore Delegato
- Jane Huang, M.D., Presidente e Direttore Medico
- Bryant Lim, Direttore Finanziario
L'evento sarà accessibile tramite webcast dal vivo sul sito web della Società nella sezione Eventi e Presentazioni, con la registrazione che rimarrà disponibile per 90 giorni. Prelude Therapeutics si specializza nello sviluppo di medicinali innovativi per i pazienti affetti da cancro, concentrandosi su:
- Degradatori SMARCA2 di prima classe (IV e orali)
- Sviluppo di inibitori CDK9
- ADCs di precisione (Conjugati Anticorpo Degradatore) attraverso partnership
Prelude Therapeutics (Nasdaq: PRLD), una empresa de oncología de precisión en etapa clínica, ha anunciado su participación en la 27ª Conferencia Global Anual de Salud de Barclays en Miami, FL, el 11 de marzo de 2025.
Los principales ejecutivos que participarán en una charla informal a las 12:30 p.m. ET incluyen:
- Kris Vaddi, Ph.D., Director Ejecutivo
- Jane Huang, M.D., Presidenta y Directora Médica
- Bryant Lim, Director Financiero
El evento será accesible a través de una transmisión en vivo en el sitio web de la Compañía en la sección de Eventos y Presentaciones, con la grabación disponible durante 90 días. Prelude Therapeutics se especializa en el desarrollo de medicamentos innovadores para pacientes con cáncer, enfocándose en:
- Degradadores SMARCA2 de primera clase (IV y orales)
- Desarrollo de inhibidores de CDK9
- ADCs de precisión (Conjugados Anticuerpo Degradador) a través de asociaciones
Prelude Therapeutics (Nasdaq: PRLD), 임상 단계의 정밀 종양학 회사가 2025년 3월 11일 플로리다 마이애미에서 열리는 바클레이스 제27회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
오후 12시 30분 ET에 진행되는 대화에 참여하는 주요 경영진은 다음과 같습니다:
- Kris Vaddi, Ph.D., 최고 경영자
- Jane Huang, M.D., 사장 겸 최고 의료 책임자
- Bryant Lim, 최고 재무 책임자
이 행사는 회사 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 실시간 웹캐스트로 접근할 수 있으며, 녹화는 90일 동안 이용 가능합니다. Prelude Therapeutics는 암 환자를 위한 혁신적인 의약품 개발에 전문화되어 있으며, 다음에 중점을 두고 있습니다:
- 1세대 SMARCA2 분해제 (IV 및 경구용)
- CDK9 억제제 개발
- 파트너십을 통한 정밀 ADCs (분해제 항체 접합체)
Prelude Therapeutics (Nasdaq: PRLD), une entreprise de cancérologie de précision en phase clinique, a annoncé sa participation à la 27e Conférence Annuelle Mondiale sur la Santé de Barclays à Miami, FL, le 11 mars 2025.
Les principaux dirigeants participant à une discussion informelle à 12h30 ET incluent:
- Kris Vaddi, Ph.D., Directeur Général
- Jane Huang, M.D., Présidente et Directrice Médicale
- Bryant Lim, Directeur Financier
L'événement sera accessible via un webcast en direct sur le site Web de la Société dans la section Événements et Présentations, avec un enregistrement disponible pendant 90 jours. Prelude Therapeutics se spécialise dans le développement de médicaments innovants pour les patients atteints de cancer, en se concentrant sur:
- Dégradateurs SMARCA2 de première classe (IV et oraux)
- Développement d'inhibiteurs de CDK9
- ADCs de précision (Conjugués d'Anticorps Dégradateurs) par le biais de partenariats
Prelude Therapeutics (Nasdaq: PRLD), ein Unternehmen der klinischen Phase im Bereich der präzisen Onkologie, hat seine Teilnahme an der 27. jährlichen globalen Gesundheitskonferenz von Barclays in Miami, FL, am 11. März 2025 bekannt gegeben.
Die wichtigsten Führungskräfte, die an einem informellen Gespräch um 12:30 Uhr ET teilnehmen, sind:
- Kris Vaddi, Ph.D., Geschäftsführer
- Jane Huang, M.D., Präsidentin und Chief Medical Officer
- Bryant Lim, Chief Financial Officer
Die Veranstaltung wird über einen Live-Webcast auf der Website des Unternehmens unter Veranstaltungen und Präsentationen zugänglich sein, wobei die Aufzeichnung 90 Tage lang verfügbar bleibt. Prelude Therapeutics ist auf die Entwicklung innovativer Medikamente für Krebspatienten spezialisiert und konzentriert sich auf:
- Erstklassige SMARCA2-Abbauprodukte (IV und oral)
- Entwicklung von CDK9-Inhibitoren
- Präzisions-ADCs (Degrader-Antikörper-Konjugate) durch Partnerschaften
- None.
- None.
WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27th Annual Global Healthcare Conference, taking place in Miami, FL on March 11, 2025.
On Tuesday, March 11, 2025, at 12:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Bryant Lim, Chief Financial Officer will participate in a fireside chat.
A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.
About Prelude Therapeutics
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.
Investor Contact:
Robert Doody
Senior Vice President, Investor Relations
Prelude Therapeutics
484.639.7235
RDoody@preludetx.com
FAQ
When is Prelude Therapeutics (PRLD) presenting at the Barclays Healthcare Conference 2025?
What are the main drug candidates in Prelude Therapeutics' (PRLD) pipeline?
How long will the webcast of PRLD's Barclays conference presentation be available?
Which executives from Prelude Therapeutics (PRLD) will participate in the Barclays conference?
What therapeutic areas does Prelude Therapeutics (PRLD) focus on?
